ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
×ðÁú¿Ê±Çë»Ø¸²ÎªÄú½â˵GLP-1 ÊÜÌ弤¶¯¼ÁµÄÉú³¤¡£
ÒȸßѪÌÇËØÑùëÄ-1£¨GLP-1£©ÊÜÌ弤¶¯¼Á½á¹¹×î¶àµÄ˳Ӧ֢Ϊ2ÐÍÌÇÄò²¡ºÍ·ÊÅÖÖ¢¡£
GLP-1 receptor agonists are now used for the treatment of type 2 diabetes and obesity.
»ØÊ×ÒÔǰ£¬´Ó·¢Ã÷GLP-1ÊÇÒȸßѪÌÇËØÔ¾Ã¸´ÙÁѽâºó±¬·¢µÄ£¬ÔÙµ½Exendent-4 µÄ·¢Ã÷¡£
Looking back, GLP-1 was found to be a cleavage product of proglucagon processing.
Exendent-4 ÊÇGLP-1Éú³¤Ê·ÉϵÄÒ»¸öÒªº¦µÄÍ»ÆÆ¡£Exendent-4ÊÇÒ»ÖÖ¶ÔGLP-1ÊÜÌå¾ßÓм¤Ðж¯Óõ«ÄܶԿ¹DPP-4½µ½âµÄëÄ¡£Ë¾ÃÀ¸ñ³ëÄÊÇÈ«ÇòÊ׿î¿Ú·þµÄGLP-1ÊÜÌ弤¶¯¼Á¡£
A key breakthrough came from the discovery of exendent-4. Exendent-4 is a peptide with agonistic properties at the GLP-1 receptor but resistance to degradation by DPP-4.Semiglutide, the first oral GLP-1 receptor agonist marked the next milestone.